Nature· 2012Q1
Comprehensive molecular characterization of human colon and rectal cancer
- 8,699citations
- Q1SCImago
- 2012year
Short summary
A genome-wide analysis of 276 colorectal cancer samples reveals that 16% are hypermutated, with distinct causes, and identifies 24 significantly mutated genes, including new targets like ERBB2 and IGF2 amplifications.
AI-generated from the title and abstract; the full text is not read.
Key points
- 16% of colorectal carcinomas are hypermutated, with 75% linked to microsatellite instability and 25% to mismatch repair or POLE mutations.
- Colon and rectal cancers share similar genomic alteration patterns when excluding hypermutated cases.
- 24 genes were found to be significantly mutated, with ARID1A, SOX9, and FAM123B identified as frequently mutated alongside known genes.
- Recurrent amplifications of ERBB2 and IGF2, and NAV2-TCF7L1 translocations represent new potential therapeutic targets.
AI-generated from the title and abstract; the full text is not read.
Abstract
To characterize somatic alterations in colorectal carcinoma, we conducted a genome-scale analysis of 276 samples, analysing exome sequence, DNA copy number, promoter methylation and messenger RNA and microRNA expression. A subset of these samples (97) underwent low-depth-of-coverage whole-genome sequencing. In total, 16% of colorectal carcinomas were found to be hypermutated: three-quarters of these had the expected high microsatellite instability, usually with hypermethylation and MLH1 silencing, and one-quarter had somatic mismatch-repair gene and polymerase ε (POLE) mutations. Excluding the hypermutated cancers, colon and rectum cancers were found to have considerably similar patterns of genomic alteration. Twenty-four genes were significantly mutated, and in addition to the expected APC, TP53, SMAD4, PIK3CA and KRAS mutations, we found frequent mutations in ARID1A, SOX9 and FAM123B. Recurrent copy-number alterations include potentially drug-targetable amplifications of ERBB2 and newly discovered amplification of IGF2. Recurrent chromosomal translocations include the fusion of NAV2 and WNT pathway member TCF7L1. Integrative analyses suggest new markers for aggressive colorectal carcinoma and an important role for MYC-directed transcriptional activation and repression. The Cancer Genome Atlas consortium reports on their genome-wide characterization of somatic alterations in colorectal cancer; in addition to revealing a remarkably consistent pattern of genomic alteration, with 24 genes being significantly mutated, the study identifies new targets for therapeutic intervention and suggests an important role for MYC-directed transcriptional activation and repression. The Cancer Genome Atlas consortium reports on their genome-wide characterization of somatic alterations in colorectal carcinoma. Combined analysis of exome sequence data, DNA copy number, promoter methylation, messenger RNA and microRNA expression, as well as low-coverage whole-genome sequencing reveal that 16% of these carcinomas have hypermutation. Of these, three-quarters have the expected high microsatellite instability, but the rest have somatic mismatch repair gene mutations. The data reveal a remarkably consistent pattern of genomic alteration, with 24 genes being significantly mutated. As well as identifying new biomarkers for aggressive colorectal carcinoma, the data imply an important role for MYC-directed transcriptional activation and repression.
The authors' abstract, as published at the source. Nature, 2012 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Pathology and Forensic Medicine
Pathology and Forensic MedicineMedicine